STEM CELL MANUFACTURING MARKET ANALYSIS

Key Developments

• On 29 May 2024 ,REPROCELL, a Biotechnology company announces the launch of Master Cell Bank (MCB) manufacturing services for Human Induced Pluripotent Stem Cells (hiPSCs) and Human Mesenchymal Stem Cells (hMSCs) intended for therapeutic applications. Utilizing strict donor recruitment processes and adhering to global regulatory standards, REPROCELL employs a proprietary footprint-free RNA reprogramming method to produce clinically relevant hiPSCs. Enhancing their capabilities, REPROCELL has integrated the Cytocentric Xvivo System model 2 from BioSpherix into their GMP Biomanufacturing Facility.
• In August 2022, Applied Stem Cell, Inc. (ASC), a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapy, augmented its Current Good Manufacturing Practice (cGMP) facility. ASC, dedicated to supporting the research community and biotechnology sector in developing and manufacturing cell and gene products, expanded its existing cGMP suite. The expansion entails the construction of four additional cGMP cleanrooms, cryo-storage facilities, process development areas, and quality control/quality assurance spaces.
• In December 2020, Sartorius AG, international pharmaceutical company entered into an agreement with Israeli cell culture media developer and manufacturer, Biological Industries, to acquire a significant stake, thereby expanding the company’s cell culture media product portfolio.
• In February 2020, Becton, Dickinson and Company revealed its strategic partnership with Babson Diagnostics for the collection of small volume blood samples in retail pharmacies.
• In May 2020, Lonza Group announced a collaboration with Moderna for the production of Moderna’s COVID-19 vaccine (mRNA-1273).